{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:26:58Z","timestamp":1790389618068,"version":"4.1.0"},"reference-count":71,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T00:00:00Z","timestamp":1312934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>DNA vaccination exploits a relatively simple and flexible technique to generate an immune response against microbial and tumor-associated antigens (TAAs). Its effectiveness is enhanced by the application of an electrical shock in the area of plasmid injection (electroporation). In our studies we exploited a sophisticated electroporation device approved for clinical use (Cliniporator, IGEA, Carpi, Italy). As the target antigen is an additional factor that dramatically modulates the efficacy of a vaccine, we selected ErbB2 receptor as a target since it is an ideal oncoantigen. It is overexpressed on the cell membrane by several carcinomas for which it plays an essential role in driving their progression. Most oncoantigens are self-tolerated molecules. To circumvent immune tolerance we generated two plasmids (RHuT and HuRT) coding for chimeric rat\/human ErbB2 proteins. Their immunogenicity was compared in wild type mice naturally tolerant for mouse ErbB2, and in transgenic mice that are also tolerant for rat or human ErbB2. In several of these mice, RHuT and HuRT elicited a stronger anti-tumor response than plasmids coding for fully human or fully rat ErbB2. The ability of heterologous moiety to blunt immune tolerance could be exploited to elicit a significant immune response in patients. A clinical trial to delay the recurrence of ErbB2+ carcinomas of the oral cavity, oropharynx and hypopharynx is awaiting the approval of the Italian authorities.<\/jats:p>","DOI":"10.3390\/cancers3033225","type":"journal-article","created":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T11:13:48Z","timestamp":1312974828000},"page":"3225-3241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans"],"prefix":"10.3390","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8151-9124","authenticated-orcid":false,"given":"Elena","family":"Quaglino","sequence":"first","affiliation":[{"name":"Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-0172","authenticated-orcid":false,"given":"Federica","family":"Riccardo","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Macagno","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Bandini","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Cojoca","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Ercole","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4634-1500","authenticated-orcid":false,"given":"Augusto","family":"Amici","sequence":"additional","affiliation":[{"name":"Department of Molecular Cellular and Animal Biology, University of Camerino, 62032 Camerino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4571-1060","authenticated-orcid":false,"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2011,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00262-010-0968-0","article-title":"2011: The immune hallmarks of cancer","volume":"60","author":"Cavallo","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"697158","DOI":"10.1155\/2010\/697158","article-title":"Vaccines and immunotherapeutics for the treatment of malignant disease","volume":"2010","author":"Aldrich","year":"2010","journal-title":"Clin. Dev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Lollini, P.L., Nicoletti, G., Landuzzi, L., Cavallo, F., Forni, G., De Giovanni, C., and Nanni, P. (2010). Vaccines and Other Immunological Approaches for Cancer Immunoprevention. Curr. Drug Targets, Epub ahead of print.","DOI":"10.2174\/138945011798184146"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00262-003-0473-9","article-title":"Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination","volume":"53","author":"Romero","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4049\/jimmunol.179.1.472","article-title":"Peptide vaccines of the HER-2\/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo","volume":"179","author":"Allen","year":"2007","journal-title":"J. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines","volume":"8","author":"Melief","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1440-1827.2009.02353.x","article-title":"Molecular pathological approaches to human tumor immunology","volume":"59","author":"Sato","year":"2009","journal-title":"Pathol. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-03-3442","article-title":"Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice","volume":"64","author":"Sakai","year":"2004","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/CJI.0b013e31818403bc","article-title":"Endritic cells: A critical player in cancer therapy?","volume":"31","author":"Palucka","year":"2008","journal-title":"J. Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10143-009-0189-1","article-title":"Dendritic-cell- and peptide-based vaccination strategies for glioma","volume":"32","author":"Yamanaka","year":"2009","journal-title":"Neurosurg. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ijc.22274","article-title":"Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB\/neuT transgenic mice","volume":"120","author":"Gallo","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.4049\/jimmunol.174.7.4228","article-title":"Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas","volume":"174","author":"Park","year":"2005","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"804","DOI":"10.2741\/1838","article-title":"Viral vectors for cancer immunotherapy","volume":"11","author":"Harrop","year":"2006","journal-title":"Front. Biosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1089\/hum.2007.127","article-title":"Therapeutic vaccination halts disease progression in BALB-neuT mice: The amplitude of elicited immune response is predictive of vaccine efficacy","volume":"19","author":"Cipriani","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/0008-5472.CAN-07-5688","article-title":"Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2\/neu vaccine","volume":"68","author":"Park","year":"2008","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1158\/0008-5472.CAN-03-2962","article-title":"Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2\/neu transgenic mice","volume":"64","author":"Quaglino","year":"2004","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/mt.2009.5","article-title":"Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: Current clinical developments","volume":"17","author":"Heller","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.4049\/jimmunol.165.9.5133","article-title":"DNA Vaccination against rat Her-2\/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB\/c mice","volume":"165","author":"Rovero","year":"2000","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1158\/0008-5472.CAN-09-2548","article-title":"A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat\/Human Chimeric Proteins","volume":"70","author":"Quaglino","year":"2010","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-09-2554","article-title":"Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity","volume":"70","author":"Jacob","year":"2010","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0065-2776(06)90005-4","article-title":"Vaccination for treatment and prevention of cancer in animal models","volume":"90","author":"Cavallo","year":"2006","journal-title":"Adv. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0167-5699(97)01201-2","article-title":"Gene vaccination: plasmid DNA is more than just a blueprint","volume":"19","author":"Tighe","year":"1998","journal-title":"Immunol. Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nm0897-849","article-title":"Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants","volume":"3","author":"Roman","year":"1997","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/108729001300338717","article-title":"From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA","volume":"11","author":"Krieg","year":"2001","journal-title":"Antisense Nucleic Acid Drug D."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2174\/156800908784293604","article-title":"Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB\/c Her-2\/neu transgenic mice","volume":"8","author":"Mastini","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrc1815","article-title":"Vaccines for tumour prevention","volume":"6","author":"Lollini","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrc2208","article-title":"Are oncoantigens suitable targets for anti-tumour therapy?","volume":"7","author":"Cavallo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Spears, M., Taylor, K.J., Munro, F.A., Cunningham, C.A., Mallon, E.A., Twelves, C.J., Cameron, D.A., Thomas, J., and Bartlett, J.M.S. (2011). In situ detection of HER2:HER2 and HER2: HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res. Treat.","DOI":"10.1007\/s10549-011-1606-z"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Quaglino, E., Mastini, C., Forni, G., and Cavallo, F. (2008). ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr. Protoc. Immunol.","DOI":"10.1002\/0471142735.im2009s82"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.4049\/jimmunol.156.9.3151","article-title":"Peptide-based, but not whole protein, vaccines elicit immunity to HER-2\/neu, oncogenic self-protein","volume":"156","author":"Disis","year":"1996","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1172\/JCI200317426","article-title":"Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2\/neu carcinomas","volume":"111","author":"Curcio","year":"2003","journal-title":"J. Clin. Invest."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.cgt.7701106","article-title":"DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice","volume":"15","author":"Curcio","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2003.11.021","article-title":"Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages","volume":"40","author":"Bibby","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrd1635","article-title":"What's wrong with our cancer models?","volume":"4","author":"Kamb","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_41","first-page":"143","article-title":"Animal models of tumor immunity, immunotherapy and cancer vaccines","volume":"171","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14796694.1.1.57","article-title":"Cancer immunoprevention","volume":"1","author":"Lollini","year":"2005","journal-title":"Future Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7626","DOI":"10.4049\/jimmunol.177.11.7626","article-title":"Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB\/c mice","volume":"177","author":"Rolla","year":"2006","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.4049\/jimmunol.0901215","article-title":"Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: Potential and limits of its therapeutic efficacy","volume":"184","author":"Rolla","year":"2010","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.4049\/jimmunol.171.11.5787","article-title":"Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines","volume":"171","author":"Piechocki","year":"2003","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1084\/jem.188.3.589","article-title":"Interleukin 12\u2013mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2\/neu transgenic mice","volume":"188","author":"Boggio","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3233\/BD-2004-20105","article-title":"Immunobiology of her-2\/neu transgenic mice","volume":"20","author":"Pannellini","year":"2004","journal-title":"Breast Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1158\/1078-0432.CCR-03-0448","article-title":"HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice","volume":"10","author":"Finkle","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","article-title":"Systemic spread is an early step in breast cancer","volume":"13","author":"Geigl","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7734","DOI":"10.1158\/0008-5472.CAN-06-1432","article-title":"Immunosurveillance of Erbb2 Carcinogenesis in Transgenic Mice Is Concealed by a Dominant Regulatory T-Cell Self-Tolerance","volume":"66","author":"Ambrosino","year":"2006","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2003-01-0190","article-title":"Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB\/c mice suppresses immune reactivity","volume":"102","author":"Melani","year":"2003","journal-title":"Blood"},{"key":"ref_52","first-page":"16","article-title":"Existent T cell and antibody immunity to Her-2\/neu protein in patients with breast cancer","volume":"54","author":"Disis","year":"1994","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.1073\/pnas.92.14.6547","article-title":"T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role","volume":"92","author":"Peoples","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1016\/S0264-410X(02)00269-4","article-title":"Electroporation improves the efficacy of DNA vaccines in large animals","volume":"20","author":"Babiuk","year":"2002","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1016\/j.vaccine.2008.03.064","article-title":"Potentiation of an anthrax DNA vaccine with electroporation","volume":"26","author":"Luxembourg","year":"2008","journal-title":"Vaccine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1128\/JVI.02437-10","article-title":"Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks","volume":"85","author":"Liu","year":"2011","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm1363","article-title":"Autoimmunity and tumor immunity induced by immune responses to mutations in self","volume":"12","author":"Engelhorn","year":"2006","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Fattori, E., Aurisicchio, L., Zampaglione, I., Arcuri, M., Cappelletti, M., Cipriani, B., Mennuni, C., Calvaruso, F., Nuzzo, M., and Ciliberto, G. (2008). Her2\/neu genetic cancer vaccine in non human primates: relevance of single nucleotide polymorphisms. Hum. Gene Ther., Epub ahead of print.","DOI":"10.1089\/hgt.2008.153"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1084\/jem.20081382","article-title":"Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response","volume":"206","author":"Rizzuto","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cellimm.2006.07.002","article-title":"Activity of DNA vaccines encoding self or heterologous Her-2\/neu in Her-2 or neu transgenic mice","volume":"240","author":"Jacob","year":"2006","journal-title":"Cell Immunol."},{"key":"ref_61","first-page":"1","article-title":"Vaccination with a plasmid DNA encoding HER-2\/neu together with low doses with metastaic breast carcinoma: a pilot clinical trial","volume":"8","author":"Norrel","year":"2010","journal-title":"J. Transl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1358\/dnp.2010.23.10.1513492","article-title":"Electroporation: A promising method for the nonviral delivery of DNA vaccines in humans?","volume":"23","author":"Frelin","year":"2010","journal-title":"Drug News Perspect."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1517\/14712598.7.11.1647","article-title":"Electroporation-based DNA immunisation: translation to the clinic","volume":"7","author":"Luxembourg","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-59745-194-9_1","article-title":"Application of electroporation gene therapy: past, current, and future","volume":"423","author":"Mir","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-59745-194-9_27","article-title":"Electroporation for drug and gene delivery in the clinic: Doctors go electric","volume":"423","author":"Gehl","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"ref_66","first-page":"145","article-title":"Electrochemotherapy: A new treatment of solid tumors","volume":"22","author":"Mir","year":"2003","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2147\/TCRM.S2780","article-title":"Cost-effectiveness analysis of electrochemotherapy with the Cliniporator\u2122 vs other methods for the control and treatment of cutaneous and subcutaneous tumors","volume":"4","author":"Colombo","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1245\/s10434-008-9976-0","article-title":"Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases","volume":"15","author":"Quaglino","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0959-8049(00)00407-X","article-title":"Effects of electrochemotherapy with bleomycin on normal liver tissue in a rat model","volume":"37","author":"Jaroszeski","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0304-4165(99)00094-X","article-title":"In vivo electroporation of skeletal muscle: Threshold, efficacy and relation to electric field distribution","volume":"1428","author":"Gehl","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-06-0500","article-title":"A new generation of mouse models of cancer for translational research","volume":"12","year":"2006","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/3\/3\/3225\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:57:02Z","timestamp":1760219822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/3\/3\/3225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,10]]},"references-count":71,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,9]]}},"alternative-id":["cancers3033225"],"URL":"https:\/\/doi.org\/10.3390\/cancers3033225","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,10]]}}}